Matching articles for "tadalafil"
Issue 1754 · May 11, 2026 Free
In Brief: Vybrique — Sildenafil Oral Film for Erectile Dysfunction

The FDA has approved Vybrique (IBSA), an oral film formulation of the phosphodiesterase type 5 (PDE5) inhibitor sildenafil, for treatment of erectile dysfunction (ED). Sildenafil oral tablets ( Viagra , and…

Med Lett Drugs Ther. 2026 May 11; 68(1754):78-9 doi:10.58347/tml.2026.1754e
The FDA has approved Vybrique (IBSA), an oral film formulation of the phosphodiesterase type 5 (PDE5) inhibitor sildenafil, for treatment of erectile dysfunction (ED). Sildenafil oral tablets ( Viagra , and generics) have been available since 1998. The manufacturer is promoting the new product as a "discreet, on-the-go" option that can be taken without water.
Issue 1715 · November 11, 2024
Eroxon — An OTC Gel for Erectile Dysfunction

The FDA has authorized over-the-counter (OTC) sale of a nonmedicated alcohol-based gel ( Eroxon – Futura) for treatment of erectile dysfunction (ED) in males ≥22 years old. Eroxon is the only FDA-approved…

Med Lett Drugs Ther. 2024 Nov 11; 66(1715):181-2 doi:10.58347/tml.2024.1715c
The FDA has authorized over-the-counter (OTC) sale of a nonmedicated alcohol-based gel ( Eroxon – Futura) for treatment of erectile dysfunction (ED) in males ≥22 years old. Eroxon is the only FDA-approved OTC and topical treatment for erectile dysfunction. It is also available in the UK and the EU.
Issue 1702 · May 13, 2024
Sotatercept (Winrevair) for Pulmonary Arterial Hypertension

The FDA has approved sotatercept-csrk ( Winrevair – Merck), a first-in-class activin signaling inhibitor, to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical…

Med Lett Drugs Ther. 2024 May 13; 66(1702):73-5 doi:10.58347/tml.2024.1702a
The FDA has approved sotatercept-csrk ( Winrevair – Merck), a first-in-class activin signaling inhibitor, to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events in adults with WHO Group 1 pulmonary arterial hypertension (PAH).
Issue 1672 · March 20, 2023
Drugs for Overactive Bladder

In overactive bladder, involuntary bladder contractions due to detrusor overactivity result in urinary urgency, frequency, nocturia, and incontinence. The prevalence of the disorder increases with age.…

Med Lett Drugs Ther. 2023 Mar 20; 65(1672):41-5 doi:10.58347/tml.2023.1672a
In overactive bladder, involuntary bladder contractions due to detrusor overactivity result in urinary urgency, frequency, nocturia, and incontinence. The prevalence of the disorder increases with age. Nonpharmacologic treatment, including bladder training, urge suppression, pelvic floor muscle exercises, constipation management, modification of fluid intake, and avoidance of dietary irritants such as alcohol and caffeine, should be tried first.
Issue 1662 · October 31, 2022
Phosphodiesterase-5 Inhibitors for Alzheimer's Disease?

A reader asked us to review use of the phosphodiesterase-5 (PDE5) inhibitor sildenafil for treatment of Alzheimer's disease (AD).

Med Lett Drugs Ther. 2022 Oct 31; 64(1662):174-5
A reader asked us to review use of the phosphodiesterase-5 (PDE5) inhibitor sildenafil for treatment of Alzheimer's disease (AD).
Issue 1658 · September 5, 2022
A Fixed-Dose Combination of Finasteride and Tadalafil (Entadfi) for BPH (online only)

The FDA has approved Entadfi (Veru), a fixed-dose combination of the 5α-reductase inhibitor finasteride and the phosphodiesterase type 5 (PDE5) inhibitor tadalafil, for initial treatment of benign prostatic…

Med Lett Drugs Ther. 2022 Sep 5; 64(1658):e1-2
The FDA has approved Entadfi (Veru), a fixed-dose combination of the 5α-reductase inhibitor finasteride and the phosphodiesterase type 5 (PDE5) inhibitor tadalafil, for initial treatment of benign prostatic hyperplasia (BPH) in men with an enlarged prostate; use of the drug is limited to 26 weeks. Entadfi is the first 5α-reductase inhibitor/PDE5 inhibitor combination to become available in the US. Finasteride ( Proscar , and generics) and tadalafil ( Cialis , and generics) are also available separately.
Issue 1649 · May 2, 2022
Drugs for Benign Prostatic Hyperplasia

About 60% of men ≥60 years old have clinically relevant prostatic enlargement due to benign prostatic hyperplasia (BPH). The goals of treatment are to decrease lower urinary tract symptoms and to prevent…

Med Lett Drugs Ther. 2022 May 2; 64(1649):65-9
About 60% of men ≥60 years old have clinically relevant prostatic enlargement due to benign prostatic hyperplasia (BPH). The goals of treatment are to decrease lower urinary tract symptoms and to prevent disease progression and complications such as acute urinary retention. The American Urologic Association's guidelines for treatment of BPH were recently updated.
Issue 1582 · October 7, 2019
Advice for Travelers

Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate issue.

Med Lett Drugs Ther. 2019 Oct 7; 61(1582):153-60
Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate issue.
Issue 1582 · October 7, 2019
Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness (online only)

View the Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness

Med Lett Drugs Ther. 2019 Oct 7; 61(1582):e161-3
View the Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness
Issue 1488 · February 15, 2016
Selexipag (Uptravi) for Pulmonary Arterial Hypertension

The FDA has approved selexipag ( Uptravi – Actelion), an oral selective prostacyclin IP receptor agonist, for treatment of pulmonary arterial hypertension (PAH). Treprostinil (Orenitram) , an oral…

Med Lett Drugs Ther. 2016 Feb 15; 58(1488):21-3
The FDA has approved selexipag ( Uptravi – Actelion), an oral selective prostacyclin IP receptor agonist, for treatment of pulmonary arterial hypertension (PAH). Treprostinil (Orenitram) , an oral prostacyclin analog, was approved earlier for this indication.
Issue 1485 · January 4, 2016
Ambrisentan (Letairis) and Tadalafil (Adcirca) for Pulmonary Arterial Hypertension

The FDA has approved the use of ambrisentan (Letairis) and tadalafil (Adcirca) together for treatment of pulmonary arterial hypertension (PAH). It is the first 2-drug regimen to be approved for this indication.

Med Lett Drugs Ther. 2016 Jan 4; 58(1485):2-4
The FDA has approved the use of ambrisentan (Letairis) and tadalafil (Adcirca) together for treatment of pulmonary arterial hypertension (PAH). It is the first 2-drug regimen to be approved for this indication.
Issue 1468 · May 11, 2015
Testosterone Nasal Gel (Natesto) for Hypogonadism

The FDA has approved an intranasal gel formulation of testosterone ( Natesto – Trimel/Endo) for replacement therapy in men with hypogonadism. Packaged in a metered-dose pump, Natesto is the first intranasal…

Med Lett Drugs Ther. 2015 May 11; 57(1468):73-4
The FDA has approved an intranasal gel formulation of testosterone ( Natesto – Trimel/Endo) for replacement therapy in men with hypogonadism. Packaged in a metered-dose pump, Natesto is the first intranasal testosterone to become available in the US. Like other testosterone products, it is classified as a schedule III controlled substance. The FDA recently cautioned against using testosterone to treat low testosterone levels solely due to aging because the benefits and safety of such use have not been established, and there is a possible increased risk of myocardial infarction (MI) and stroke.
Issue 1466 · April 13, 2015
Advice for Travelers

Patients planning to travel to other countries often ask for information about prevention of diarrhea, malaria, and other travel-related conditions. Vaccines recommended for travelers based on their…

Med Lett Drugs Ther. 2015 Apr 13; 57(1466):52-8
Patients planning to travel to other countries often ask for information about prevention of diarrhea, malaria, and other travel-related conditions. Vaccines recommended for travelers based on their destination, length of stay, and planned activities were reviewed in a previous issue.
Issue 1442 · May 12, 2014
Avanafil (Stendra) - Another PDE5 Inhibitor for Erectile Dysfunction

The FDA has approved avanafil ( Stendra – Vivus), an oral phosphodiesterase type-5 (PDE5) inhibitor, for treatment of erectile dysfunction. It is the fifth PDE5 inhibitor to be approved for this indication.…

Med Lett Drugs Ther. 2014 May 12; 56(1442):37-8
The FDA has approved avanafil ( Stendra – Vivus), an oral phosphodiesterase type-5 (PDE5) inhibitor, for treatment of erectile dysfunction. It is the fifth PDE5 inhibitor to be approved for this indication. Advertisements on Stendra ’s website imply that it has a faster onset of action than other PDE5 inhibitors.
Issue 1437 · March 3, 2014 Free
In Brief: Testosterone and Cardiovascular Risk

Prompted by the recent publication of 2 retrospective studies, the FDA has announced that it is investigating the risk of stroke, heart attack, and death in men taking FDA-approved testosterone products. 1 The…

Med Lett Drugs Ther. 2014 Mar 3; 56(1437):17
Prompted by the recent publication of 2 retrospective studies, the FDA has announced that it is investigating the risk of stroke, heart attack, and death in men taking FDA-approved testosterone products. 1 The first study examined the records of 8709 men with low testosterone levels (<300 ng/dL) who underwent coronary angiography between 2005 and 2011; 1223 of these men started testosterone therapy after a median of 531 days following coronary angiography. Three years after coronary angiography, the Kaplan-Meier estimated cumulative percentages of men who died or had a myocardial infarction (MI) or ischemic stroke were 26% of those treated with testosterone and 20% of those who were not treated with the hormone, a hazard ratio of 1.29 (95% CI 1.04-1.58; P=0.02). 2 The second study compared the rate of nonfatal MI during the 90 days after filling a prescription with the rate in the prior year in 56,000 men given a prescription for testosterone and in 167,000 given a phosphodiesterase type 5 inhibitor (sildenafil [Viagra] or tadalafil [Cialis] ). In the testosterone group as a whole, the post/pre-prescription rate ratio was 1.36, but in men ≥65 years old it was 2.19 and in younger men with a history of heart disease it was 2.90. In men who received a prescription for sildenafil or tadalafil, the rate ratio was 1.08 for all ages, 1.15 for those ≥65 years old, and 1.40 for younger men with a history of heart disease. 3 A recent meta-analysis of randomized, placebo-controlled trials of testosterone therapy also found an increased risk of cardiovascular-related events in men treated with the hormone (odds ratio [OR] 1.54; 95% CI 1.09-2.18); an analysis by funding source found that the risk was greater in trials not funded by the pharmaceutical industry (OR 2.06 vs. 0.89). 4 1. FDA Drug Safety Communication January 31, 2014: FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products. Available at www.fda.gov. Accessed February 24, 2014. 2. R Vigen et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013; 310:1829. 3. WD Finkle et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014; 9:e85805. 4. L Xu et al. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 2013; 11:108. Download complete U.S. English article
Issue 1437 · March 3, 2014
Riociguat (Adempas) for Pulmonary Hypertension

The FDA has approved the sGC stimulator riociguat (rye" oh sig' ue at; Adempas – Bayer) for oral treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)…

Med Lett Drugs Ther. 2014 Mar 3; 56(1437):17-9
The FDA has approved the sGC stimulator riociguat (rye" oh sig' ue at; Adempas – Bayer) for oral treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) following surgery or when surgery is not an option. It is the first drug to be approved for treatment of CTEPH.
Issue 1436 · February 17, 2014
Macitentan (Opsumit) for Pulmonary Arterial Hypertension

The FDA has approved macitentan (ma" si ten' tan; Opsumit – Actelion), for oral treatment of pulmonary arterial hypertension (PAH). Macitentan is the second nonselective endothelin receptor antagonist…

Med Lett Drugs Ther. 2014 Feb 17; 56(1436):15-6
The FDA has approved macitentan (ma" si ten' tan; Opsumit – Actelion), for oral treatment of pulmonary arterial hypertension (PAH). Macitentan is the second nonselective endothelin receptor antagonist approved for PAH. It is a derivative of bosentan (Tracleer) , which is also manufactured by Actelion, and is scheduled to become available generically in 2015. Riociguat (Adempas) , another new drug for this indication, will be reviewed in a future issue. Volibris
Issue 1429 · November 11, 2013
A Prostatic Urethral Lift for Benign Prostatic Hyperplasia

The FDA has approved the use of a permanent prostatic urethral lift implant ( UroLift – NeoTract) to relieve low or blocked urine flow in men ≥50 years old with benign prostatic hyperplasia (BPH).

Med Lett Drugs Ther. 2013 Nov 11; 55(1429):91
The FDA has approved the use of a permanent prostatic urethral lift implant ( UroLift – NeoTract) to relieve low or blocked urine flow in men ≥50 years old with benign prostatic hyperplasia (BPH).
Issue 1383 · February 6, 2012
PDE5 Inhibitors for Erectile Dysfunction

Sildenafil (Viagra) , tadalafil (Cialis) and vardenafil (Levitra, Staxyn) have become the standard treatment for erectile dysfunction. Head-to-head comparisons of these agents are still lacking, but some…

Med Lett Drugs Ther. 2012 Feb 6; 54(1383):10-1
Sildenafil (Viagra) , tadalafil (Cialis) and vardenafil (Levitra, Staxyn) have become the standard treatment for erectile dysfunction. Head-to-head comparisons of these agents are still lacking, but some differences between them and new recommendations for their dosing (see Table 2) are worth noting.
Issue 1377 · November 14, 2011
Tadalafil (Cialis) for Signs and Symptoms of Benign Prostatic Hyperplasia

The FDA has approved the use of the phosphodiesterase-5 (PDE-5) inhibitor tadalafil ( Cialis – Lilly) for treatment of signs and symptoms of benign prostatic hyperplasia (BPH) in men with or without erectile…

Med Lett Drugs Ther. 2011 Nov 14; 53(1377):89-90
The FDA has approved the use of the phosphodiesterase-5 (PDE-5) inhibitor tadalafil ( Cialis – Lilly) for treatment of signs and symptoms of benign prostatic hyperplasia (BPH) in men with or without erectile dysfunction. Tadalafil is approved for use under another brand name (Adcirca) for treatment of pulmonary arterial hypertension. The other PDE-5 inhibitors available in the US for treatment of erectile dysfunction (sildenafil [Viagra] ; vardenafil [Levitra] ) have also been reported to be effective for treatment of BPH signs and symptoms, but have not been approved for this indication by the FDA.
Issue 1283 · April 7, 2008
Tadalafil (Cialis) Once a Day for Erectile Dysfunction

The phosphodiesterase type 5 (PDE5) inhibitor tadalafil ( Cialis - Lilly) is now being promoted for once daily treatment of erectile dysfunction. Tadalafil differs from sildenafil ( Viagra ) and vardenafil…

Med Lett Drugs Ther. 2008 Apr 7; 50(1283):27-8
The phosphodiesterase type 5 (PDE5) inhibitor tadalafil ( Cialis - Lilly) is now being promoted for once daily treatment of erectile dysfunction. Tadalafil differs from sildenafil ( Viagra ) and vardenafil (Levitra) , the other PDE5 inhibitors marketed for erectile dysfunction in the US, in having a much longer duration of action.
Issue 1218 · September 28, 2005
BiDil for Heart Failure

BiDil (NitroMed), a fixed-dose combination of isosorbide dinitrate and hydralazine, was approved by the FDA for adjunctive use in the treatment of heart failure in black patients.Both drugs are oral…

Med Lett Drugs Ther. 2005 Sep 28; 47(1218):77-8
BiDil (NitroMed), a fixed-dose combination of isosorbide dinitrate and hydralazine, was approved by the FDA for adjunctive use in the treatment of heart failure in black patients.Both drugs are oral vasodilators that have been used together off-label for many years to treat heart failure in patients not responding to other drugs.
Issue 1215 · August 15, 2005
Sildenafil (Revatio) for Pulmonary Arterial Hypertension

The Medical Letter reported last year that sildenafil ( Viagra - Pfizer) appeared to be effective for idiopathic pulmonary arterial hypertension (PAH), but confirmation from a controlled trial was needed. Now…

Med Lett Drugs Ther. 2005 Aug 15; 47(1215):65-7
The Medical Letter reported last year that sildenafil ( Viagra - Pfizer) appeared to be effective for idiopathic pulmonary arterial hypertension (PAH), but confirmation from a controlled trial was needed. Now the results of such a study are about to be published, and the drug has been approved by the FDA for this indication under the trade name Revatio .
Issue 1212 · July 4, 2005
CYP3A and Drug Interactions

Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in…

Med Lett Drugs Ther. 2005 Jul 4; 47(1212):54-5
Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in the metabolism of more than 50 percent of currently prescribed drugs.2 CYP3A4, which is more abundantly expressed than CYP3A5, accounts for most CYP3A activity in vivo .
Issue 1211 · June 20, 2005
Viagra and Loss of Vision

The FDA recently announced that it was investigating 38 reports of loss of vision in men who took sildenafil (Viagra) , which has been used to treat erectile dysfunction since 1998.

Med Lett Drugs Ther. 2005 Jun 20; 47(1211):49
The FDA recently announced that it was investigating 38 reports of loss of vision in men who took sildenafil (Viagra) , which has been used to treat erectile dysfunction since 1998.
Issue 1173 · January 5, 2004
Drug Interactions with Grapefruit Juice

The ability of grapefruit juice to increase serum concentrations of drugs was first discovered during a study of the effect of ethanol on felodipine (Plendil) pharmacokinetics. Double-strength grapefruit juice…

Med Lett Drugs Ther. 2004 Jan 5; 46(1173):2-4
The ability of grapefruit juice to increase serum concentrations of drugs was first discovered during a study of the effect of ethanol on felodipine (Plendil) pharmacokinetics. Double-strength grapefruit juice used to disguise the taste of ethanol resulted in higher than expected serum concentrations of felodipine (DG Bailey et al, Clin Invest Med 1989; 12:357).
Issue 1172 · December 22, 2003
Tadalafil (Cialis) for Erectile Dysfunction

Tadalafil ( Cialis - Lilly Icos) is the third oral drug to be approved by the FDA for treatment of erectile dysfunction. It has a longer duration of action than sildenafil ( Viagra ) or vardenafil ( Levitra -…

Med Lett Drugs Ther. 2003 Dec 22; 45(1172):101-2
Tadalafil ( Cialis - Lilly Icos) is the third oral drug to be approved by the FDA for treatment of erectile dysfunction. It has a longer duration of action than sildenafil ( Viagra ) or vardenafil ( Levitra - Medical Letter 2003; 45:77 ).
Issue 1166 · September 29, 2003
Vardenafil (Levitra) for Erectile Dysfunction

Vardenafil (Levitra -Bayer) is the second oral drug approved by the FDA for treatment of erectile dysfunction. Sildenafil (Viagra - Medical Letter 1998; 40:51), the first oral drug, has been available for 5…

Med Lett Drugs Ther. 2003 Sep 29; 45(1166):77-8
Vardenafil (Levitra -Bayer) is the second oral drug approved by the FDA for treatment of erectile dysfunction. Sildenafil (Viagra - Medical Letter 1998; 40:51), the first oral drug, has been available for 5 years. Pharmacokinetics, effectiveness, adverse effects, dosage and cost of the new drug are reviewed. Whether it offers any benefits over sildenafil is discussed.